Can yogurt and kimchi boost cancer treatment?
NCT ID NCT06337552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether eating 3-6 servings of fermented foods daily (like yogurt, kefir, and sauerkraut) can improve how well cancer treatments work in patients with locally advanced rectal cancer or non-small cell lung cancer. The 39 participants are randomly assigned to either the fermented food diet or standard care. Researchers will measure tumor response, gut microbiome changes, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fermented foods (yogurt, cottage cheese, kefir, kombucha, sauerkraut, kimchi)
- What this could lead to
- If it works, this diet could help improve how well cancer treatments work and boost quality of life for patients with rectal or lung cancer.
- What could go wrong
- This is a small, early-stage trial with only 39 participants, so results may not apply to everyone. The diet is an add-on, not a replacement for standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
39 people
The number who actually took part.
- Started
-
Apr 2024
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for GI Patients: * 18 years of age or older * Diagnosed with locally advanced rectal cancer (Stage II-III) * Will undergo neoadjuvant chemoradiation at Moffitt Cancer Center * Able to pick up FFs once/weekly at Moffitt * Able to speak and read English * Able to consume foods orally * Able to provide informed consent Inclusion Criteria for Thoracic Patients: * 18 years of age or older * Diagnosed with stage II-IV non-small cell lung cancer (NSCLC) * Will undergo Immunotherapy with immune checkpoint inhibitors (+/- chemotherapy or other treatment) at Moffitt Cancer Center * Able to pick up FFs once/weekly at Moffitt * Able to speak and read English * Able to consume foods orally * Able to provide informed consent Exclusion Criteria: * Antibiotic use within 1 month prior to baseline * If currently using probiotics, unwillingness to cease probiotic use * Previous receipt of surgery, immunotherapy, chemotherapy, or radiation for a colon or rectal tumor * Per clinician's discretion, clinician confirmed inflammatory bowel conditions (e.g., ulcerative colitis, Crohn's disease) * Infectious disease diagnosed \<1 month prior to baseline * Already consuming ≥2 servings of fermented foods/day * Previously diagnosed with a mast cell disorder or histamine allergy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Immunotherapy added to standard treatment aims to save the anus in Ultra-Low rectal cancer
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans